Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?
- 161 Downloads
The growth hormone (GH) nadir during oral glucose tolerance test (OGTT) is the gold standard diagnostic test for acromegaly. The utility of OGTT-GH suppression test in patients with abnormal glucose metabolism (AGM) has not been well established. In this study, we compared the GH nadir during OGTT in patients evaluated for acromegaly in the presence and absence of AGM.
This is a retrospective cohort study of patients with acromegaly (G1, n = 40) and a group in whom acromegaly was not confirmed (G2, n = 53) who had OGTT-GH suppression test during 2000–2012, using a monoclonal GH immunoenzymatic assay. The patients were categorized as having normal glucose metabolism (NGM) or AGM. GH nadir during OGTT in each group were compared.
In G1 and G2, 17 and 19 patients had AGM, respectively. Among 17 patients with diabetes, median HbA1C was 7% (range 5.7–9.6%). All except one patient had HbA1C< 8%. There was no difference in the GH nadir in patients with or without AGM within G1 (p = 0.15) and G2 (p = 0.43). All G1 patients with AGM had GH nadir > 0.4 µg/L. Four G1 patients with NGM had GH nadir<0.4 µg/L. All G2 patients had GH nadir < 0.4 µg/L, except one with NGM and GH nadir of 0.4 µg/L.
Using highly sensitive GH assay, a GH nadir ≥ 0.4 µg/L during the OGTT-GH suppression test may be used for diagnosis of acromegaly in patients with AGM in the absence of poorly controlled diabetes.
KeywordsGrowth hormone nadir Acromegaly Diagnosis OGTT Diabetes
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 1.S.K. Subbarayan, M. Fleseriu, M.B. Gordon, J.A. Brzana, L. Kennedy, C. Faiman, B.A. Hatipoglu, R.A. Prayson, J.B. Delashaw, R.J. Weil, A.H. Hamrahian, Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated IGF-1 but normal glucose-suppressed growth hormone. Endocr. Pract. 18(6), 817–825 (2012). https://doi.org/10.4158/EP11324.OR CrossRefGoogle Scholar
- 9.A. Bereket, C.H. Lang, S.L. Blethen, M.C. Gelato, J. Fan, R.A. Frost, T.A. Wilson, Effect of insulin on the insulin-like growth factor system in children with new-onset insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 80(4), 1312–1317 (1995). https://doi.org/10.1210/jcem.80.4.7536205 Google Scholar
- 10.K.L. Clayton, J.M. Holly, L.M. Carlsson, J. Jones, T.D. Cheetham, A.M. Taylor, D.B. Dunger, Loss of the normal relationships between growth hormone, growth hormone-binding protein and insulin-like growth factor-I in adolescents with insulin-dependent diabetes mellitus. Clin. Endocrinol. (Oxf.). 41(4), 517–524 (1994)CrossRefGoogle Scholar
- 13.P. Fainstein Day, J.A. Fagin, R.M. Vaglio, L.E. Litwak, M.F. Picasso, R.A. Gutman, Growth hormone-insulin-like growth factor-I axis in adult insulin-dependent diabetic patients: evidence for central hypersensitivity to growth hormone-releasing hormone and peripheral resistance to growth hormone. Horm. Metab. Res. 30(12), 737–742 (1998)CrossRefGoogle Scholar
- 14.H. Hanaire-Broutin, B. Sallerin-Caute, M.F. Poncet, M. Tauber, R. Bastide, J.J. Chale, R. Rosenfeld, J.P. Tauber, Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM. Diabetologia 39(12), 1498–1504 (1996)CrossRefGoogle Scholar
- 15.C.M. Asplin, A.C. Faria, E.C. Carlsen, V.A. Vaccaro, R.E. Barr, A. Iranmanesh, M.M. Lee, J.D. Veldhuis, W.S. Evans, Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 69(2), 239–245 (1989). https://doi.org/10.1210/jcem-69-2-239 CrossRefGoogle Scholar
- 18.C.H. Anderwald, A. Tura, A. Gessl, S. Smajis, C. Bieglmayer, R. Marculescu, A. Luger, G. Pacini, M. Krebs, Whole-body insulin sensitivity rather than body-mass-index determines fasting and post-glucose-load growth hormone concentrations. PLoS ONE 9(12), e115184 (2014). https://doi.org/10.1371/journal.pone.0115184 CrossRefGoogle Scholar
- 20.N. Hattori, A. Shimatsu, Y. Kato, H. Koshiyama, Y. Ishikawa, H. Assadian, T. Tanoh, M. Nagao, H. Imura, Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly. J. Clin. Endocrinol. Metab. 70(3), 771–776 (1990). https://doi.org/10.1210/jcem-70-3-771 CrossRefGoogle Scholar
- 21.M.J. Kayath, E.M. Russo, S.A. Dib, J.G. Vieira, Do impaired glucose tolerance and diabetes mellitus interfere with the interpretation of the growth hormone response to the oral glucose tolerance test? Braz. J. Med. Biol. Res. 25(5), 449–455 (1992)Google Scholar
- 22.P. Dutta, S. Singhal, N.K. Sachdeva, V.N. Shah, A. Pathak, K.K. Mukherjee, A. Bhansali, Diagnostic utility of serum GH, IGF-1 and IGFBP3 in patients of acromegaly with uncontrolled diabetes: a pilot study. J. Assoc. Physicians India 62(8), 686–690 (2014)Google Scholar
- 25.L. Katznelson, J.L. Atkinson, D.M. Cook, S.Z. Ezzat, A.H. Hamrahian, K.K. Miller; American Association of Clinical, E., American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. Endocr. Pract. 17, 1–44 (2011)CrossRefGoogle Scholar
- 26.S. Melmed, F. Casanueva, F. Cavagnini, P. Chanson, L.A. Frohman, R. Gaillard, E. Ghigo, K. Ho, P. Jaquet, D. Kleinberg, S. Lamberts, E. Laws, G. Lombardi, M.C. Sheppard, M. Thorner, M.L. Vance, J.A. Wass, A. Giustina, Consensus statement: medical management of acromegaly. Eur. J. Endocrinol. 153(6), 737–740 (2005). https://doi.org/10.1530/eje.1.02036 CrossRefGoogle Scholar
- 27.A.M. Arafat, M. Mohlig, M.O. Weickert, F.H. Perschel, J. Purschwitz, J. Spranger, C.J. Strasburger, C. Schofl, A.F. Pfeiffer, Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J. Clin. Endocrinol. Metab. 93(4), 1254–1262 (2008). https://doi.org/10.1210/jc.2007-2084 CrossRefGoogle Scholar
- 28.I. Bancos, A. Algeciras-Schimnich, W.W. Woodmansee, A.K. Cullinane, L.J. Donato, T.B. Nippoldt, N. Natt, D. Erickson, Determination of nadir growth hormone concentration cutoff in patients with acromegaly. Endocr. Pract. 19(6), 937–945 (2013). https://doi.org/10.4158/EP12435.OR CrossRefGoogle Scholar